Astana Biomed Group, an authorized Abcam distributor in Central Asia

Human TDRD7 knockout A549 cell lysate (ab258227)

Overview

  • Product name

    Human TDRD7 knockout A549 cell lysate
    See all TDRD7 kits

  • Product overview


    Knockout cell lysate achieved by CRISPR/Cas9.

  • Parental Cell Line

    A549

  • Organism

    Human

  • Mutation description

    Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon8 and 2 bp deletion in exon8 and 2 bp insertion in exon8.

  • Passage number

  • Knockout validation

    Sanger Sequencing

  • Reconstitution notes

    To use as WB control, resuspend the lyophilizate in 50 µL of LDS* Sample Buffer to have a final concentration of 2 mg/ml. For reducing conditions, we recommend a final concentration of 0.1 M DTT.

    *Usage of SDS sample buffer is not recommended with these lyophilized lysates.

  • Notes

    Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version - found here. Please refer to our lysis protocol for further details on how our lysates are prepared.

    User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

    Access thousands of knockout cell lysates, generated from commonly used cancer cell lines.
    See here for more information on knockout cell lysates.

    Abcam has not and does not intend to apply for the REACH Authorisation of customers’ uses of products that contain European Authorisation list (Annex XIV) substances.
    It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

    This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Properties

Target

  • Sequence similarities

    Contains 2 Tudor domains.

  • Cellular localization

    Cytoplasm. Present in chromatoid body (CB) of spermatids (mammalian counterpart of germplasm, pole plasm or polar granules in Drosophila germ cells), also named processing bodies (P-bodies) in somatic cells. Detected in the multilobular cytoplasmic CBs (also called intermitochondrial cementin) in pachytene spermatocytes and as a single perinuclear CB in haploid round spermatids.
  • Information by UniProt

  • Form

    Found in a mRNP complex, at least composed of TDRD1, TDRD6, TDRD7 and DDX4. Found in a complex containing CABLES1, CDK16 and CDK17. Interacts with CABLES1, CDK17 and PIWIL1.

  • Alternative names

    • CATC4
    • KIAA1529
    • PCTAIRE 2
    • PCTAIRE2 binding protein
    • PCTAIRE2 BP
    • PCTAIRE2-binding protein
    • PCTAIRE2BP
    • RP11-508D10.1
    • TDRD 7
    • Tdrd7
    • TDRD7_HUMAN
    • TrAP
    • Tudor domain containing 7
    • Tudor domain-containing protein 7
    • Tudor repeat associator with PCTAIRE 2
    see all

Properties

Images

  • Sanger Sequencing - Human TDRD7 knockout A549 cell lysate (ab258227)
    Sanger Sequencing - Human TDRD7 knockout A549 cell lysate (ab258227)

    Allele-1: 2 bp deletion in exon8

     

  • Sanger Sequencing - Human TDRD7 knockout A549 cell lysate (ab258227)
    Sanger Sequencing - Human TDRD7 knockout A549 cell lysate (ab258227)

    Allele-2: 1 bp deletion in exon8

     

  • Sanger Sequencing - Human TDRD7 knockout A549 cell lysate (ab258227)
    Sanger Sequencing - Human TDRD7 knockout A549 cell lysate (ab258227)

    Allele-3: 2 bp insertion in exon8

     

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up